With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...
“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...
In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s ...
Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. | Amid a dramatic reshaping of the federal ...
It's not yet been a week since Marty Makary, M.D., was confirmed to lead the FDA as its commissioner. | Peter Marks, M.D., Ph ...
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...
Lilly continues full-court press against breast cancer with women's March Madness event sponsorships
As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback